Bolt Biotherapeutics, Inc. 8-K

What Happened Bolt Biotherapeutics, Inc. announced its financial results for the quarter ended March 31, 2026 and provided a business update in a press release dated May 12, 2026. The company furnished that press release to the SEC as Exhibit 99.1 in an 8-K filing; the filing states the exhibit is "furnished" (not "filed") and therefore is not subject to certain liabilities under the federal securities laws.

Key Details

• Company: Bolt Biotherapeutics, Inc. (BOLT).
• Event: Press release announcing Q1 2026 financial results and business update, dated May 12, 2026, for the quarter ended March 31, 2026.
• Filing: Form 8-K furnished to the SEC on May 12, 2026; Exhibit 99.1 contains the press release.
• Signature: The 8-K is signed by William P. Quinn, President, Chief Executive Officer and Chief Financial Officer.

Why It Matters The 8-K notifies investors that Bolt has released its quarterly earnings and a business update; investors should read the Exhibit 99.1 press release for the specific financial figures (revenue, operating results, cash position) and operational developments. The filing’s "furnished, not filed" status means the press release is provided for disclosure but is not incorporated into other SEC filings and carries limited statutory liability compared with filed materials.